Clinical experiences of Lipo PGE1(R)in Buerger's disease
- Author:
Dong Ik KIM
1
;
Ki Hyuk PARK
;
Seung HUH
;
Hang Seok CHANG
;
Byung Boong LEE
Author Information
1. Department of Surgery, Sung Kyun Kwan University Medical College, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Buerger's disease;
Prostaglandin E1
- MeSH:
Alprostadil;
Foot;
Gingiva;
Hemorrhage;
Humans;
Liver Function Tests;
Thromboangiitis Obliterans
- From:Journal of the Korean Society for Vascular Surgery
1997;13(1):54-58
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Twenty patients with Buerger's disease who were not candidates for reconstructive arterial surgery were treated by PGE1(Lipo PGE1(R) ) for 1 Month. All patients were injected with 50microgram of alprostadil intravenously once a day. Clinical effects were evaluated by improvement of ischemic symptom and healing rate on gangrenous foot and side effects. Clinical efficacy by combined assessment of markedly improved, improved, slightly improved was 70%. 5 of 8 patient who had gangrenous foot showed improved healed state. Adverse effect was found in only one patient who had minimal gum bleeding. However there was no deterioration on chemical profile including CBC, liver function test, urinary analysis, CRP and ESR. The results suggest that Lipo PGE1(R) has a beneficial effect on Buerger's disease without significant adverse effect.
